Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.8600
+0.0120 (1.42%)
At close: Jul 11, 2025, 4:00 PM
0.8949
+0.0349 (4.06%)
After-hours: Jul 11, 2025, 7:57 PM EDT
Biofrontera Revenue
Biofrontera had revenue of $8.59M in the quarter ending March 31, 2025, with 8.54% growth. This brings the company's revenue in the last twelve months to $38.00M, up 14.28% year-over-year. In the year 2024, Biofrontera had annual revenue of $37.32M with 9.54% growth.
Revenue (ttm)
$38.00M
Revenue Growth
+14.28%
P/S Ratio
0.15
Revenue / Employee
$408,570
Employees
93
Market Cap
8.12M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BFRI News
- 12 days ago - Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment - GlobeNewsWire
- 4 weeks ago - BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG - GlobeNewsWire
- 5 weeks ago - Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book - GlobeNewsWire
- 2 months ago - Biofrontera Inc. (BFRI) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 2 months ago - Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris - GlobeNewsWire
- 2 months ago - Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025 - Accesswire
- 2 months ago - Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis - GlobeNewsWire